首页> 外文OA文献 >Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and ≥12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan

【2h】

Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and ≥12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan

机译：有效性，安全性和甲氨蝶呤剂量逐渐变细，用催风瘤菌和≥12毫克/周的甲氨蝶呤对早期类风湿性关节炎的甲氨蝶呤进行治疗多年来：日本鹰期刊监测研究的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Yoshiya Tanaka; Tsuneyo Mimori; Hisashi Yamanaka; Naomi Sunaga; Kazuo Morita; Junko Kimura; Tsutomu Takeuchi;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and >= 12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan [J] . Modern rheumatology . 2020,第3期

机译：两年内治疗服用Adalimalab的有效性，安全性和甲氨蝶呤剂量逐渐变细纹，> = 12mg /周的早期类风湿性关节炎的甲氨蝶呤：日本鹰邮票监测研究的结果
2. Effectiveness and safety of initiating adalimumab plus >= 12 mg/week methotrexate with adjustable dosing in biologic-naive patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan [J] . Tanaka Yoshiya, Mimori Tsuneyo, Yamanaka Hisashi, Modern rheumatology . 2019,第4期

机译：发起Adalimalab Plus> = 12mg /周的甲氨蝶呤的疗效和安全性与生物幼稚关节炎的生物幼稚患者可调剂量：鹰研究日本船长监测
3. Long-term safety and effectiveness of adalimumab for the treatment of Japanese patients with rheumatoid arthritis: 3-year results from a postmarketing surveillance of 552 patients [J] . Harigai Masayoshi, Tsuchiya Tsuyoshi, Kawana Katsuyoshi, Modern rheumatology . 2018,第1期

机译：Adalimumab治疗日本类风湿性关节炎患者的长期安全性和有效性：3年度的552例患者的下市监测结果
4. Development and characterization of methotrexate loaded poly(L-lactic acid) microspheres for the treatment of rheumatoid arthritis. [D] . Liang, Sanching Linda. 2006

机译：甲氨蝶呤负载聚（L-乳酸）微球的开发和表征，用于治疗类风湿关节炎。
5. Adalimumab with Methotrexate in Treatment-Naïve Japanese Patients with Rheumatoid Arthritis at Risk of Progressive Structural Joint Damage: A Postmarketing Observational Study [O] . Yukiko Ito, Kaori Hozumi, Yukiko Okada, 2017

机译：阿达木单抗联合甲氨蝶呤治疗未治疗的日本类风湿关节炎患者具有进行性结构性关节损伤的风险：上市后观察性研究
6. Effectiveness and safety of initiating adalimumab plus ≥12 mg/week methotrexate with adjustable dosing in biologic-naïve patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan [O] . Yoshiya Tanaka, Tsuneyo Mimori, Hisashi Yamanaka, 2018

机译：发起Adalimalab Plus≥12毫克/周的有效性和安全性与早期类风湿性关节炎的生物学 - 诺韦患者可调剂量的甲氨蝶呤：日本鹰研究船长监测

Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and ≥12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan

著录项

相似文献

相关主题

期刊订阅